Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Medpace Holdings, Inc. (MEDP) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $601,87, with a market capitalisation of $16,62B and a P/E ratio of 35,24. Over the past 52 weeks, its price has ranged from $373,00 to $677,90. This page covers its latest market performance, valuation, price trends and company information.
$16,62B | |
$620,35 | |
$677,90 | |
$21,76 | |
$620,48 | |
3,00 | |
294,22K | |
35,24 | |
$677,90 | |
$373,00 | |
-- | |
-- |
Medpace Holdings, Inc. (MEDP) is trading at $601,87 in pre-market trading as of 2026-09-16 12:04:00, down 3,00% ($18,61) from the previous close of $620,48
Pre-market trading shows how investors are pricing MEDP before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Medpace Holdings, Inc. (MEDP) moved from $591,29 to $601,87, representing a gain of 1,79% ($10,58).
The stock traded between $577,64 and $623,03 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 200,10 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 75,1%
MEDP is currently trading at $601,87, placing it 75,1% of the way from its 52-week low of $373,00 to its 52-week high of $677,90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 6500 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Medpace Holdings, Inc. (MEDP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.